The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Share News (VAL)

Share Price Information for ValiRx (VAL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.15
Bid: 3.10
Ask: 3.20
Change: -0.10 (-3.08%)
Spread: 0.10 (3.226%)
Open: 3.25
High: 3.25
Low: 3.10
Prev. Close: 3.25
VAL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK WINNERS & LOSERS: Phorm Jumps; Supermarkets Rebound

Thu, 03rd Oct 2013 11:39

LONDON (Alliance News) - The following stocks are the leading risers and fallers on the main London indices midday Thursday.

-------

FTSE 100 - Winners

Aviva shares, up 2.5%, are the biggest risers on the blue-chip index. The financial services provider announced Wednesday that it had completed the sale of its US operations to Athene Holding Ltd in a deal worth USD2.6 billion, some USD800 million more than previously announced.

J Sainsbury, up 1.2%, and Tesco, up 1%, are big gainers. The food retailers are rebounding from Wednesday's lows after investors reacted negatively to their trading statements. Sainsbury's is benefiting from Nomura increasing its price target to 370 pence from 350p. Similarly, Citigroup upgraded Tesco to Neutral from Sell, raising its price target to 350 from 285. However, Deutsche Bank, JP Morgan and Macquarie have all cut Tesco's price target. Both companies are trading close to pre-announcement levels.

BP climbs 0.9% after the Financial Times reported Thursday that it had reached a milestone in its legal battle to limit its compensation settlement for the 2010 Deepwater Horizon disaster. The FT announced that the oil and gas company had received a favourable ruling from a US court. The court on Wednesday night approved an injunction to stop payments to businesses that had not "experienced actual injury traceable to loss" from the Deepwater Horizon accident, overturning an earlier decision. The ruling may improve BP's chances of preventing the cost of the settlement rising beyond double its original estimate of USD7.8 billion.

-------

FTSE 100 - Losers

Sports Direct International, down 2%. The company announced that Chief Executive Officer Dave Forsey and Group Finance Director Bob Mellors, exercised options granted to them under the company's executive bonus share scheme, by acquiring 1.0 million shares and then each selling 950,000 them at a price of 680.0 pence per share on Wednesday. The 50,000 shares each retained by Forsey and Mellors are their only holdings in sporting good company, representing 0.01% stakes.

William Hill falls 1.5% after the company warned that gross win margins in sports betting were below the year before. In its interim management statement for the 13 weeks ended October 1, the company said its overall quarterly performance was impacted by quiet July trading in Retail together with lower results-linked gross win margins in the quarter. Analysts at Numis remain upbeat, but note that profits have fallen short of expectations by GBP20 million.

Standard Chartered drops 0.9% in the aftermath of Numis downgrading its recommendation. Numis cuts Standard Chartered's recommendation to Hold from Add, decreasing its price target to 1,500 pence from 1,780p. The downgrades are made as Numis reduces its 2013-2014 forecasts for Standard Chartered by 5%. Currency depreciation across a large number of Standard Chartered's operational territories has hit the international banking group hard. Numis estimates that currency alone reduces estimates by 2%. Weak third-quarter financial markets volumes also are to blame.

-------

FTSE 250 - Winners

BTG, up 1.4%. The healthcare company raised its full-year revenue guidance due to recent acquisitions it has made and said its performance the first half of the year had met its expectations. It now expects revenues in the year to March 31, 2014 to be between GBP275 million and GBP285 million, up from previous guidance of between GBP235 million and GBP245 million, after making progress in integrating the targeted therapies division of Nordion Inc., and EKOS Corporation, deals that it completed in July. In a trading update, the company said new varicose vein treatment Varisolve is still progressing through a new drug application review in the US, and it is pushing ahead with preparations for a commercial launch in the first six months of the 2014 calendar year.

-------

FTSE 250 - Losers

Ophir Energy, down 4%. The oil-and-gas producer said Wednesday that it had successfully completed the Pweza-3 appraisal well and flow test in Block 4, Tanzania. However, the stock falls for a second day as the market has little interest in appraisals until there are further farm-out announcements, says Cannacord analyst Charlie Sharp. A farm-out announcement is an agreement to outsource production of discoveries, rather than simply reporting the discoveries.

-------

AIM - Winners

Phorm Corporation, up 64%. The company has been boosted after it said that it had launched operations of its advertising platform in mainland China. The internet personalisation technology company has begun a nationwide opt-in process, and in its first week of operations has seen an average of 4.3 million users a day. It said that it was in negotiations with publishers and advertisers and had begun the commercialisation process of its operations. In the coming months the company will start its test campaigns, it said, before moving to commercial operations.

Desire Petroleum climbs 31%. Falkland Oil and Gas Limited and Desire Petroleum PLC have announced that they have reached an GBP61 million agreement for Falkland to acquire the entire share capital of Desire in exchange for FOGL shares. The oil and gas exploration and development companies, both operating in the Falkland Island Basins, said that both boards believe the deal will diversify the activities of both companies and improve finances. Following the deal, FOGL shareholders will own 60% of the combined group share capital with Desire shareholders owning the remaining 40%.

Evocutis shares jump 24% as the company rebounds from Wednesday's lows. Evocutis was a big faller Wednesday as it announced that it is to convene a general meeting on October 28 after its net assets fell to less than half of its share capital. The company said that it was no longer in discussions with potential offerers in relation to a merger or sale of the company. Evocutis shares are still a long way off pre-announcement levels.

Quoram is up 16% despite making a GBP2.0 million pretax loss for the year to June 30, compared with a loss of GBP728,000 last year. The company has announced that it is confident about the prospects for its first investment since making the transition from oil-and-gas explorer to investing company, AIM-listed Plant Health Care PLC. Quoram said Plant Health Care, which makes products that increase crop yields, could benefit from the rise in the world's population to over seven billion people and the subsequent increase in demand for food.

Alecto Minerals, up 16%. The African-focussed multi-commodity exploration and development company is widely expected to complete the acquisition of AME West Africa from Savannah Resources in the next few days.

Byotrol is up 9.8 % after it said it has entered into an agreement to acquire all of the issued shares that it does not currently own in its consumer products joint venture, Byotrol Consumer Products Limited. Byotrol Consumer Products was established in 2007 as a joint venture between Byotrol and ?What If! Innovation Capital Nominees Limited.

Varirx is up 8.1% on the back of the news that it has filed a Phase IB/dose escalation study for its anti-cancer therapeutic, VAL201. This filing is required before approval is able to be granted. ValiRx said the trial on prostate cancer patients will be a first in-man study with real patients and will not require health volunteers. A first in-man study is a clinical trial where a medical procedure, previously developed and assessed through in vitro or animal testing, or through mathematical modelling is tested on human subjects for the first time.

-------

AIM - Losers

Albemarle & Bond, down 11%, continues to fall, albeit at a slower rate, after it announced Wednesday that it was in talks with its lenders about solving potential breaches of its debt covenants later this year after discussion with its largest shareholder about an equity raising failed.

Noricum Gold is down 11% as investors react badly to the news that it has raised GBP2 million to develop its Rotgulden Gold and Precious Metals project in Austria. The gold exploration and development company said it raised the cash via an oversubscribed placing of 200 million new ordinary shares, diluting the price of existing shares.

-------

By James Kemp; jameskemp@alliancenews.com; @jamespkemp

Copyright 2013 Alliance News Limited. All Rights Reserved.

More News
31 Mar 2023 16:39

TRADING UPDATES: FireAngel signs with British Gas; Shanta pours gold

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more
1 Mar 2023 20:09

TRADING UPDATES: Ediston signs 10-year lease with Marks & Spencer

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
1 Mar 2023 14:26

ValiRx incorporates new wholly-owned lab subsidiary

(Sharecast News) - Life science company ValiRx announced the incorporation of a new wholly-owned subsidiary, Inaphaea BioLabs, on Wednesday.

Read more
3 Feb 2023 13:41

TRADING UPDATES: Somero revenue short of outlook; SigmaRoc optimistic

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
26 Jan 2023 15:44

UK shareholder meetings calendar - next 7 days

Friday 27 January 
Avon Protection PLCAGM
Henderson Far East Income LtdAGM
Ixico PLCAGM
NB Global Monthly Income Fund LtdEGM re proposed managed wind-down
On The Beach Group PLCAGM
Pathfinder Minerals PLCGM re capital raise
Serica Energy PLCGM re consideration shares approval
Treatt PLCAGM
Monday 30 January 
Bluebird Merchant Ventures LtdAGM
Contango Holdings PLCAGM
Hollywood Bowl Group PLCAGM
SkinBioTherapeutics PLCGM re annual report review
Starwood European Real Estate Finance LtdEGM re capital return 
Webis Holdings PLCAGM
Tuesday 31 January 
Hydrogen Future Industries PLCAGM
Mobile Streams PLCAGM
Residential Secure Income PLCAGM (TBC)
Star Phoenix Group LtdGM re removal and appointment of auditor
Team PLCAGM
Yamana Gold IncSGM re transaction with Agnico Eagle Mines Ltd and Pan American Silver Corp
Zamaz PLCAGM
Wednesday 1 February 
Baronsmead Second Venture Trust PLCAGM
Baronsmead Venture Trust PLCAGM
Capricorn Energy PLCGM re directors removal and appointment of new directors
Catalyst Media GroupAGM
Hyve Group PLCAGM
Imperial Brands PLCAGM
Premier Miton Group PLCAGM
Renew Holdings PLCAGM
Schroder Asia Pacific Fund PLCAGM
Thursday 2 February 
abrdn Equity Income Trust PLCAGM
Alteration Earth PLCAGM
Baillie Gifford European Growth Trust PLCAGM
JPMorgan Indian Investment Trust PLCAGM
Sage Group PLCAGM
Schroder European Real Estate Investment Trust PLCAGM
Tectonic Gold PLCAGM
ValiRx PLCGM re fundraising
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
17 Jan 2023 21:40

TRADING UPDATES: Future Metals in JV; Gunsynd sells stake in investee

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
13 Jan 2023 13:31

IN BRIEF: ValiRx seeks up to GBP1.5 million for new research facility

ValiRx PLC - Hatfield Heath, England-based life sciences company focused on early-stage cancer therapeutics and women's health - Raises GBP1 million from placing of 9.1 million shares at 11 pence each. Also will raise up to GBP500,000 more from a broker offer to retail investors at the same price. Turner Pope Investments Ltd will run the broker offer. Every four shares in the placing and retail offer come with a warrant to buy another new share at 14p over the next three years. Calls February 2 general meeting to approve the fund raise. Currently has a GBP10.1 million market capitalisation.

Read more
6 Dec 2022 11:31

ValiRx shares fall on test extension, but optimistic of other assets

(Alliance News) - ValiRx PLC on Tuesday saw shares drop, after extending its evaluation agreement with Hokkaido University to conduct further experimental testing.

Read more
24 Oct 2022 12:47

ValiRx forms new majority-owned breast cancer subsidiary

(Sharecast News) - Women's health and cancer therapeutics company ValiRx announced the formation of a new partially-owned subsidiary, Cytolytix, on Monday, which had signed an intellectual property licence agreement with King's College London (KCL).

Read more
24 Oct 2022 10:05

ValiRx teams with King's College London for cancer project

(Alliance News) - ValiRx PLC on Monday said it is making progress on its goal to introduce new academic projects into its portfolio, after launching subsidiary company Cytolytix Ltd and signing a licence agreement with King's College London.

Read more
8 Sep 2022 11:47

IN BRIEF: ValiRx shares up on new interim chief scientific officer

ValiRx PLC - Nuneaton, England-based drug development company - Appoints Catherine Tralau-Stewart as interim chief scientific officer. Says she has experience working across leading pharmaceutical companies and academic groups. Tralau-Stewart will review new, incoming science; enhance the progress of existing projects; and influence the overall strategic scientific direction of the company, ValiRx adds. Chief Executive Suzy Dilly comments: "I'm looking forward to having another in-house scientist with whom to share ideas and to develop and deliver upon our strategic ambitions. Cathy's wealth of experience in exactly the areas in which we wish to progress, makes her an excellent choice for this role."

Read more
31 Aug 2022 13:51

EARNINGS UPDATES: Windward widens loss as operating expenses rise

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
13 Jul 2022 14:44

IN BRIEF: ValiRx shares jump on breast cancer drug candidate progress

ValiRx PLC - Nuneaton, England-based drug development company - Completes the evaluation of the impact of a peptide drug candidate against triple negative breast cancer. Evaluation concludes there is "good evidence" of biological activity and a "strong" rationale for further development. Adds that the drug candidate was investigated over nine months. Tests also demonstrate promising data on ovarian cancer cells, in addition to the targeted breast cancer cells. As a result, ValiRx has notified the academic team and intellectual property & licensing team at King's College London that it wants to proceed to full in-licensing.

Read more
5 Jul 2022 15:51

IN BRIEF:ValiRx gains GBP1.0 million from Turner Pope broker option

ValiRx PLC - Nuneaton, England-based drug development company - Announces that the broker option granted to Turner Pope Investments Ltd has been fully subscribed and raises GBP1.0 million before expenses.

Read more
30 Jun 2022 17:31

TRADING UPDATES: M&C Saatchi expects to deliver on annual profit

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.